2022-04-21| Technology

These Two Companies are Helping Push Denmark to the Forefront of Biotech

by Reed Slater
Share To
Two Denmark-based biotech companies, SNIPR Biome and TOOsonix, are experiencing their own set of ‘firsts’ with their respective technologies. SNIPR Biome, which specializes in CRISPR-based therapies, will undergo its first Phase 1 clinical trial on humans to evaluate the safety and effectiveness of reducing Escherichia coli (E. coli) colonization using their novel CRISPR-based therapeutics, SNIPR001.

TOOsonix centers around high-intensity focused ultrasound (HIFU) systems for various skin treatments. They will take aim at Basal Cell Carcinoma (BCC) in their first clinical study on the treatment with their System ONE-M device, a HIFU system capable of focusing energy in hyper-specific locations and depths to target affected skin areas. 

Denmark is one of the leading nations in Europe in the biotechnology industry. In 2021 alone, Danish biotech startups received $434 million in venture capital to further pioneer life-saving medicines used globally. This article will highlight two such companies’ momentous strides in extending Denmark’s biotech industry internationally. 

GO Prime with only $1.49 now

Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
Discrimination Leads to Rapid Aging, Science Shows the Detrimental Effects of this Act
A New Study has Linked Treatment Resistant Depression to Body Mass Index
AI Reveals Sex-Related Brain Differences and Precision Medicine Potential
The EU Sustainability Directive’s Influence on Pharmaceutical Supply Chains
New UC Berkeley Study Challenges Traditional Views on Lactate and Carbohydrate Metabolism
First Person to Receive Transplanted Pig Kidney has Died
Scroll to Top